Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2024-08-23 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年半年度报告' which translates to '2024 Semi-Annual Report'. It covers the period from January 1, 2024 to June 30, 2024, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, and management discussion and analysis. It also contains sections on company overview, business segments, risk disclosures, and financial statements. The length is substantial (15,000 characters) and it contains actual financial statements and substantive financial data. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-23 Chinese
马应龙2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 年半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, revenue, and other financial metrics. It also includes sections on business operations and analysis for the first half of 2024. The document length is 3726 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The content matches the characteristics of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and management discussion. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-23 Chinese
马应龙关于产业投资基金延长存续期的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the board of 马应龙药业集团股份有限公司 regarding the extension of the duration of an industrial investment fund. It details the background of the fund, the specific changes to the partnership agreement extending the fund's term by one year, and the impact of this change on the company. The document is relatively short (1175 characters) and does not contain financial statements, audit information, or detailed financial data. It is an update on a financing-related matter (investment fund duration extension) but does not report new financing or capital raising activities. It is not a full financial report, earnings release, or regulatory certification. Given the nature of the announcement about a fund's operational change, it best fits the category of Capital/Financing Update (CAP).
2024-08-20 Chinese
马应龙关于全资子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary receiving a drug registration certificate from the National Medical Products Administration. It details the drug's specifications, approval, and potential impact on the company. The document is short (1043 characters) and serves as a formal notification of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not an announcement of voting results, nor a call transcript or capital update. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant company event that does not fit other specific categories.
2024-08-06 Chinese
马应龙2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an announcement regarding the implementation of the 2023 annual equity distribution (dividend payment) by the company 马应龙药业集团股份有限公司. It details the dividend per share, relevant dates for record, ex-dividend, and payment, the shareholders' meeting approval date, and tax withholding information. It does not contain financial statements or comprehensive financial data but focuses on dividend distribution details and logistics. The document length is 2373 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Notice of Dividend Amount (DIV).
2024-07-19 Chinese
马应龙关于全资子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about its wholly-owned subsidiary receiving a drug registration certificate from the national drug regulatory authority. It details the drug's specifications, approval, and market impact. The document is short (979 characters) and serves as a regulatory announcement about a product approval, not a financial report, management change, or shareholder meeting material. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-05 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.